Medium-Term Management Plan
ASKA Pharmaceutical Holdings
Mid-Term Management Plan 2028
Positioning of Mid-Term Management Plan 2028 and Growth Strategy
The Mid-Term Management Plan 2028 serves as the first phase of the roadmap toward realizing ASKA VISION
2035. Based on a strategy consisting of two foundations and five strategic pillars, the plan aims to
achieve both the steady growth of existing businesses and the establishment of future growth platforms,
thereby building a sustainable earnings base.
By the final year of the plan, fiscal 2028, ASKA
Pharmaceutical Holdings aims to achieve net sales of ¥85.0 billion. At the same time, the Company will
further strengthen its business foundation with a view toward the early achievement of ¥100.0 billion in
net sales, supporting long-term sustainable growth.
- Our Purpose
- Our Vision
Mid-Term Management Plan 2028
- Slogan
FY2028 Financial Targets
-
Net Sales
¥85.0billion -
Operating Profit Margin
10% -
ROE
10% -
Total payout ratio
40%
The Five Pillars Driving Growth
-
Domestic
PharmaceuticalStrengthening
Profitability through
Further Expansion
in Specialty Areas -
Drug Discovery
Accelerating Global Expansion
-
Global
Strengthening Business Foundations through New Plant Operations
-
Animal
HealthExpanding Business through
New Product Launches and Overseas Expansion -
Testing and
Around-the-PillExpanding the Testing Business through Trace Analysis Technologies and Broadening into Adjacent Healthcare Fields
Two Strategic Foundations
-
Financial Strategy
Advanced management with a focus on the cost of capital
-
Strengthening the Management Foundation
Strengthening the management infrastructure to execute strategies
6 Material Issues
-
1
Promotion of environmental management
-
2
Developing diverse human resources to enhance corporate value
-
3
Contributing to women's health and animal health
-
4
Stable supply of high-quality products and provision of appropriate information
-
5
Respect for human rights
-
6
Strengthening governance
ASKA Pharmaceutical Holdings' VISION 2035
To achieve sustainable growth and continue contributing to society over the next decade and beyond, ASKA Pharmaceutical Holdings has established its “Vision for 2035.” Through purpose-driven business management and execution, we will realize our Vision for 2035 and continue creating value for all stakeholders.
Management Policy
Guided by our long-term vision, ASKA VISION 2035, the Group is committed to purpose-driven management
to remain a company that is trusted by society and continuously creates sustainable value.
In our
core prescription pharmaceuticals business, we will further expand our presence in specialty areas,
particularly in the fields of obstetrics and gynecology and thyroid disorders. At the same time, we will
continue to contribute to healthcare by strengthening drug discovery research and leveraging open
innovation to create pharmaceuticals that address evolving societal needs.
Building on our
established business foundation, we will further expand our global business while advancing into the
animal health and testing & around-the-pill businesses. Through these initiatives, we aim to become
a Total Healthcare Company that covers the entire healthcare value chain—from prevention, testing, and
diagnosis to treatment and prognosis—while expanding our business both in Japan and overseas.
In
addition, under the Mid-Term Management Plan 2028, we will advance our growth strategy based on the Five
Pillars and Two Strategic Foundations. By enhancing management with a strong awareness of capital costs
and strengthening our management foundation, we will improve profitability and achieve sustainable
growth in corporate value.
Mid-Term Management Plan 2028: Financial Targets
The Mid-Term Management Plan 2028 represents the first phase of the roadmap toward realizing ASKA
VISION 2035. Through the dual pursuit of steady growth in existing businesses and the establishment of
future growth platforms, the Plan aims to build a sustainable earnings base.
By the final year of the
Plan, fiscal 2028, the Company targets net sales of ¥85.0 billion. At the same time, it will continue to
strengthen its business foundation with a view toward the early achievement of ¥100.0 billion in net
sales, supporting the next stage of growth and long-term value creation.
FY2028 Financial Targets
-
Net Sales
¥85.0billion -
Operating Profit Margin
10% -
ROE
10% -
Total payout ratio
40%
Mid-Term Management Plan 2028: Growth Strategy
Under the Mid-Term Management Plan 2028, we will execute our growth strategy based on the Five Pillars and Two Strategic Foundations.
The Five Pillars Driving Growth
The Group has identified the businesses that will drive its future growth as the Five Pillars. By strategically allocating management resources to these priority areas, we will accelerate growth and strengthen our long-term competitiveness.
-
We will further strengthen our presence in specialty areas, particularly in the fields of obstetrics and gynecology and thyroid disorders, which represent our core therapeutic areas. Looking ahead to future business growth, we will continue contributing to society by addressing health issues arising from sex-based differences. To support expansion into new therapeutic areas, we will actively pursue the acquisition of new rights and the enhancement of our pipeline, while making strategic investments with a view not only to the Japanese market but also to commercialization across Asia.
In addition, we will continue building the foundation for offering new treatment options beyond pharmaceuticals by advancing the development of launch and service infrastructures for our digital therapeutics currently under development. Through these initiatives, we aim to strengthen our earnings base and achieve sustainable growth. -
To establish a leading position in specialty areas both in Japan and overseas, we will strengthen our drug discovery research platform, with a focus on gynecological disease models and ion channel–targeted drug discovery. In addition, through the promotion of open innovation, we will incorporate new modalities, including antibodies and mid-sized molecules, to further enhance our drug discovery capabilities.
We will also maximize the value of our assets through out-licensing and collaborative development partnerships, creating medium- to long-term revenue opportunities. Furthermore, we will continue advancing our pipeline into later stages of clinical development while promoting the global expansion of proprietary assets, including AKP-009 and AKP-017. Through these initiatives, we aim to strengthen our global presence and establish a sustainable growth platform. -
At Hataphar in Vietnam, we will strengthen our business foundation through the operation of a new manufacturing facility scheduled to commence commercial production in 2026. Leveraging this new plant, we will expand our portfolio of competitive products, including specialty products, to increase market share and improve profitability.
We will also accelerate business expansion across Southeast Asia, with a particular focus on Vietnam and the Philippines. In addition to enhancing our product supply capabilities to address local market needs, we will increase our presence in overseas markets through initiatives such as the introduction of ASKA products and the expansion of our regional business operations. -
We will continue to expand our portfolio of products for both livestock and companion animals, focusing on areas where we have established strengths, including reproduction and endocrinology. In overseas markets, we will accelerate expansion primarily across Asia through the introduction of veterinary pharmaceuticals, supplements, and other products, thereby generating revenue opportunities at an early stage.
Through the continued growth of our Animal Health business, we aim to contribute to a society in which people and animals can live together in harmony. -
We will expand the adoption of our non-invasive hormone measurement kits while leveraging our proprietary trace mass spectrometry technologies to broaden our business in the around-the-pill field. In addition, through collaboration with startup companies, we will pursue opportunities in healthcare areas that can generate synergies with our prescription pharmaceuticals business.
Through these initiatives, we aim to establish new revenue streams and build a sustainable foundation for future growth.
Two Strategic Foundations
In addition to the Five Pillars Driving Growth, which serve as the primary engines of growth, the Group has identified Two Strategic Foundations as the key enablers that support sustainable growth from both management and financial perspectives. These foundations provide the organizational and financial infrastructure necessary to execute our growth strategy and enhance long-term corporate value.
-
Financial Strategy
Advanced management with a focus on the cost of capital
Under a management approach that emphasizes capital efficiency, we will improve capital productivity through the introduction of management practices utilizing ROIC (Return on Invested Capital). We also recognize the enhancement of PBR (Price-to-Book Ratio) as a key management priority and will actively pursue initiatives to improve market valuation.
Based on these principles, we will strive to achieve an optimal balance between growth investments and shareholder returns through disciplined capital allocation. In addition, investments in research and development as well as M&A opportunities will be executed selectively and with a strong focus on capital efficiency, strategic fit, and long-term value creation. -
Strengthening the Management Foundation
Strengthening the management infrastructure to execute strategies
To reinforce the management foundation that supports sustainable growth, we will advance initiatives across four key areas: governance, human capital, digital transformation (DX), and ESG. To further strengthen corporate governance, we have transitioned from a Company with an Audit & Supervisory Board to a Company with an Audit and Supervisory Committee. In conjunction with this transition, we have increased the proportion of independent outside directors to a majority of the Board, thereby enhancing both management transparency and oversight functions.
In addition, we will continue investing in human capital to develop the next generation of business leaders and highly skilled professionals. At the same time, we will promote digital transformation to enhance business processes, improve operational efficiency, and increase productivity, thereby strengthening the Group’s long-term competitiveness and sustainable growth potential.
Mid-Term Management Plan 2028 Presentation Materials
Review of Mid-Term Plan
Review of the Previous Mid-Term Management Plan
Evolution of the Mid-Term Management Plans
Since transitioning to a holding company structure in 2021, the Group has advanced the Mid-Term Management Plan 2025, strengthening its presence in specialty areas and expanding into new business domains. Building on these achievements, we have established our long-term vision, ASKA VISION 2035, and positioned the Mid-Term Management Plan 2028 as the first phase of its implementation roadmap. Through these initiatives, we aim to achieve sustainable growth and further enhance our corporate value.
Achievements and Progress of the Previous Mid-Term Management Plan
In the fiscal year ended March 2026, the final year of the Mid-Term Management Plan 2025, the Group achieved net sales of ¥71.1 billion, an operating margin of 8.2%, and ROE of 8.0%. As a result, we successfully attained all of the financial targets set forth in the Plan, including net sales of ¥70.0 billion, an operating margin of 8%, and ROE of 8%.
Progress Chart
| FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 (Forecast) |
|
|---|---|---|---|---|---|---|---|
| Net Sales | 55,181 | 56,607 | 60,461 | 62,843 | 64,139 | 71,127 | 73,000 |
| OPM | 6.5% | 8.5% | 8.4% | 10.3% | 8.3% | 8.2% | 8.5% |
| ROE | 6.3% | 8.8% | 8.2% | 13.0% | 8.0% | 8.0% |
Overview of Financial Results for Fiscal Year Ended March 2026
The economic environment during the fiscal year ended March 2026 remained uncertain despite signs of a
gradual recovery in Japan. Rising geopolitical risks, foreign exchange fluctuations, and continued
inflation in resource and raw material prices placed upward pressure on costs. In the pharmaceutical
industry, the business environment remained challenging due to ongoing healthcare cost containment
measures, including regular drug price revisions, as well as rising raw material and manufacturing
costs.
Despite these conditions, the Group achieved increases in both revenue and profit, driven
primarily by the strong performance of key products. As a result, all financial targets set forth in the
Mid-Term Management Plan 2025—net sales of ¥70.0 billion, an operating margin of 8%, and ROE of 8%—were
successfully achieved.
Consolidated net sales for the fiscal year increased by ¥7.0 billion year on year to ¥71.1 billion.
This was primarily attributable to the continued strong performance of products in the obstetrics and
gynecology field within the prescription pharmaceuticals business, as well as the consolidation of Ha
Tay Pharmaceutical Joint Stock Company (Hataphar), a Vietnamese pharmaceutical company that had
previously been accounted for using the equity method.
Although the cost of sales ratio increased by
0.9 percentage points from the previous fiscal year, resulting in cost of sales of ¥37.0 billion, gross
profit increased by ¥2.8 billion year on year to ¥34.1 billion due to higher revenue. Selling, general
and administrative expenses rose by ¥2.3 billion to ¥28.3 billion, mainly reflecting increased
investment in research and development. As a result, operating profit increased by ¥0.5 billion to ¥5.8
billion.
Ordinary profit amounted to ¥5.7 billion, reflecting non-operating income of ¥740 million
and non-operating expenses of ¥908 million. Profit attributable to owners of parent increased by ¥323
million year on year to ¥5.4 billion, supported by gains on the sale of investment securities and fixed
assets, partially offset by a loss on the valuation of investment securities.
Progress and Achievements of Key Strategic Initiatives
The Seven Strategic Initiatives identified as key priorities under the Mid-Term Management Plan 2025 progressed largely in line with plan. The Group achieved significant milestones, including attaining the No. 1 annual sales position in the obstetrics and gynecology market, strengthening its research and development capabilities, and expanding its business footprint across Southeast Asia through strategic collaborations with Hataphar and MedChoice. These achievements have contributed to the enhancement of the Group’s competitiveness and the establishment of a foundation for future growth.
| Strategy | Key Achievements |
|---|---|
| Corporate value enhancement through strengthened initiatives in specialty areas |
|
| Continuous creation of new drugs through cutting-edge drug discovery |
|
| Expansion of overseas business |
|
| Provision of new value aimed at the realization of Total Healthcare |
|
| Improvement of operational efficiency, reduction of costs, and strengthening of financial foundation |
|
| Fostering of an organizational culture that emphasizes compliance and reliability |
|
| Human resources development for the realization of growth strategy |
|
Business Environment
In addition to market changes such as annual drug price revisions under medical cost containment policies, issues related to pharmaceutical quality and supply, and the increasing difficulty of drug discovery, the environment continues to be highly challenging. This is further compounded by changes in the international situation, including the Russia–Ukraine conflict, global supply chain disruptions, and rising costs of energy, raw materials, and labor.
Changes in the Obstetrics and Gynecology Market
The obstetrics and gynecology market, which is the core of our group's ethical pharmaceuticals business, is expected to grow continuously.
Investors' Guide (Fiscal Year Ended March 2026)
Changes in the Environment Surrounding Women
Promotion of National Policies on Women’s Empowerment
- Inclusion in the Basic Policy 2024 and Women’s Version of the Basic Policy 2024
- Support for balancing women’s health issues—such as menstruation, pregnancy/childbirth, and menopause—with work
- Introduction of the Gynecology-Specific Disease Treatment Management Fee (2020)
- Insurance coverage for infertility treatment (2022)
Women’s Advancement in Society and Lifestyle Changes
- Increase in the number of female employees and women in management positions
- Greater understanding of women’s health issues, improved health literacy, and increased exposure through media and social networks
Advances in Medical Technology and Access Related to Women’s Diseases
- Expansion of high-quality pharmaceuticals, particularly in Asia, to enhance presence
- Diversification of treatments for dysmenorrhea and infertility
- Expansion of internet access and online medical consultations
The Group's Share of the Obstetrics and Gynecology Market
Share of the Group's growth drivers, the uterine fibroid and endometriosis treatment RELUMINA and the dysmenorrhea treatment product line.
Investors' Guide (Fiscal Year Ended March 2026)
Risks and Opportunities
At ASKA Pharmaceutical Holdings, we identify the most critical issues to address by properly analyzing
the current situation and the associated “opportunities” and “risks” from the perspective of their
relevance to our businesses and social contribution, with the aim of achieving sustainable growth across
the Group.
In particular, by focusing on materialities where our strengths can be maximized—namely
“Contributing to women’s health and animal health”—the entire Group works on each initiative, thereby
contributing to the achievement of the SDGs.
Impact of
Drug Price Revisions Aimed at Containing Medical Costs, and
Our Strategic Shift toward New Drug
Development
Government drug price revisions containing medical costs previously took place biennially but shifted to an annual basis in 2021. Amid this persistent risk of drug price reductions, the business climate for pharmaceutical companies is more challenging than ever. Although there have been positive signs in such forms as repricing for unprofitable drugs in areas of high medical needs (aimed at ensuring a stable supply of pharmaceuticals while also addressing higher raw material costs) and premiums to promote innovation in drug discovery, annual drug price revisions continue to have a significant impact, with price cuts for generic drugs tending to surpass those for brand-name drugs. In response, the Group has focused on new drug development, seeking to increase the weighting of brand-name drugs with a view to stabilizing margins. We aim to realize sustained growth by continuing to roll out innovative new drugs.
ASKA Pharmaceutical’s Brand-name Drug Ratio, Drug Price Revision Rate, and Impact Rate
Financial and Capital Strategy
Strengthening capital efficiency management
and
financial strategy to maximize corporate value
(Updated: September 2025)
Business Environment Facing Execution of Our Medium-Term Management Plan
The ASKA Pharmaceutical Holdings Group is steadily advancing Medium-Term Management Plan 2025 to
achieve sales of ¥70 billion, an operating profit margin of 8%, and ROE of 8% in FY2025, the final year
of the plan. In FY2024, we achieved record-high sales of approximately ¥64 billion and both the
operating profit margin and ROE exceeded 8%, attesting to steady progress in implementing the measures
outlined in our growth strategy.
These results fill us with confidence in our ability to meet the
targets set in Medium-Term Management Plan 2025, as we also expect FY2025 sales to get a boost from
Hataphar, the Vietnamese pharmaceutical company that we recently made a consolidated subsidiary.
Currently, the domestic market for pharmaceuticals is experiencing headwinds in the form of structural
factors such as annual drug price revisions and a declining domestic population, creating a highly
challenging business environment for the industry. Pharmaceutical R&D entails risks such as extended
development periods and uncertainty over the probability of success. As evidenced by numerous reports of
competitors suspending or halting development of new drugs, R&D efforts do not always yield the
expected results.
Under these conditions, we believe that for the Group to continue enhancing
corporate value over the longer term, it is essential that we take a strategic approach to building out
and managing the business portfolio going forward, including in new businesses and domains, in addition
to enhancing the value of products and expanding the pipeline programs in our therapeutic areas.
Under Medium-Term Management Plan 2025, the ASKA Pharmaceutical Holdings Group aims to become a “total
healthcare company with a strong foundation as a specialty pharma company.” To achieve the goals set in
this plan, we have devised four visions and seven strategies. Among the latter is “Overseas
operations.”
Although the domestic market for prescription pharmaceuticals is expected to remain flat
or shrink, in countries in Southeast Asia and other areas the pharmaceutical market is expanding amid a
rapid increase in medical needs driven by population growth, rising income levels, and women’s
advancement in society. Vietnam, in particular, is regarded as a high-growth market in view of its
population of over 100 million, political stability, and good public order. Vietnam has a GDP growth
rate of roughly 5–6% and its pharmaceutical market is worth an estimated approximately ¥630 billion,
expanding at a brisk CAGR of 9.4%.
Like Vietnam, the Philippines is a country maintaining stable GDP growth while continuing to expand its
economy. Currently, its economic growth rate is a robust 5-6%. The Philippines’ population is now
approximately 112.72 million* and its pharmaceutical market is worth an estimated approximately ¥700
billion, with more growth projected. Furthermore, the Philippines ranks third in East Asia and the
Pacific in the World Economic Forum’s Global Gender Gap Index, demonstrating progress in the advancement
of women in society.
On the other hand, the Philippines is also known for regional disparities in
medical infrastructure and access to healthcare.
The Group believes that the Philippines represents a promising market in which we can create new growth opportunities through a strategy of addressing the health issues of local women, drawing on strengths cultivated over many years in Japan including our track record of stably supplying high-quality products, our expertise in Ob/Gyn, and our know-how concerning educational activities.
*Source: Japan External Trade Organization (JETRO)
FY2024 Progress toward Medium-Term Plan Targets and Future Challenges
Under the new holding company structure, our businesses comprise the pharmaceutical business, the animal health business, the testing business, and the overseas business. We seek to maximize our corporate value by drawing on these businesses’ collective knowledge, technologies, and know-how, and by fully leveraging synergies among Group companies.
In the pharmaceutical business, it is difficult to sustain growth with existing products alone, given annual drug price revisions and patent cliffs. To maintain stable profitability, it is essential to continue developing or acquiring products with strong growth potential. To “Continuously create new drugs through advanced drug discovery,” one of the seven strategies outlined in Medium-Term Management Plan 2025, we are ramping up development and in-licensing activities with a view to fleshing out our pipeline, and accelerating efforts to enhance our discovery research structure.
In FY2024, we in-licensed a new basic technology for ion channel drug discovery, expanding our research focus beyond the three existing priority areas of internal medicine, Ob/Gyn, and urology. New drug discovery is a long-term undertaking that can span decades and requires substantial investment. However, we believe that by expanding our revenue base by launching new drugs, we can enhance corporate value over the medium to long-term. We will continue to make strategic investments with this long-term perspective in mind.
To date, our animal health business has centered on products for industrial livestock such as cattle
and pigs. Recently, though, the companion animal market has been expanding as growth in stay-at-home
demand since the COVID-19 pandemic has been accompanied by an increase in households keeping cats and
dogs as pets. We plan to further expand our business in this field, and if we are to accurately address
market needs in both the industrial and companion animal spheres we think it is important to actively
pursue non-organic growth opportunities such as new product launches and M&A.
In the testing
business, while working to build up our presence in the clinical testing field, we are also actively
expanding into the pet market, launching a feline hyperthyroidism test kit and a feline stress test kit
in March 2025.
Products such as these contribute to pet health management from an animal welfare
standpoint. As a new initiative, we also launched a business focused on measuring environmental
pollutants and began accepting contracts to measure levels of PFAS (per- and polyfluoroalkyl substances)
in blood and water. We are developing and launching a range of test and measurement kits to meet the
diverse needs of modern society, seeking also to help solve environmental issues.
In our overseas business, we think it essential to pursue business in collaboration with partner
companies well versed in local conditions. In addition to making Hataphar a consolidated subsidiary in
February 2025, we acquired roughly 20% of shares in Philippine pharmaceutical group FTS Ambrose, making
it an equity-method affiliate and establishing a collaborative framework with FTS Ambrose group company
MedChoice Pharma.
MedChoice Pharma’s strength lies in the endocrine field, specifically in thyroid
hormone agents, where it has the second-largest market share in the Philippines. We aim to accurately
meet local medical needs by harnessing both our expertise in raising awareness of thyroid diseases in
the Japanese market, and our extensive experience in building a stable supply system. Through open
innovation, the Group pursues not only in-house drug discovery but also in-licensing opportunities and
joint research and development with external partners. Beginning in FY2024, we launched a research grant
program for domestic academia to foster new collaboration opportunities based on promising technologies.
We are accelerating the formulation of our next medium-term management plan, incorporating input from the frontlines of our pharmaceuticals, animal health, testing, and overseas businesses. In addition to strengthening our domestic operations centered on the growing Ob/Gyn field, we are pursuing expansion into high-growth overseas markets. We have set targets for sales and other indicators by backcasting from our envisioned position 10 years from now, and are working to formulate a sustainable and actionable growth strategy that also considers non-organic growth.
Optimizing Management That is Conscious of Cost of Capital and Share Price
We have identified price-to-book ratio (PBR) improvement as an important issue for management, and one that we addressed in 2023 when we issued the press release “ASKA Pharmaceutical Holdings Takes Action to Implement Management That is Conscious of Cost of Capital and Share Price.” In this press release, we outlined three initiatives to implement such management under the headings “Growth Strategy,” “Strengthen Shareholder Returns,” and “Strengthen IR Activities.”
Under Growth Strategy, we are working to strengthen our pharmaceutical business, establish new
businesses, and expand overseas, harnessing open innovation and external collaborations to strengthen
our position in specialty areas. We plan to maintain or expand R&D investment at a level slightly
above 10% of sales, positioning R&D as a key driver of sustainable growth. In our bid to become a
total healthcare company, we are also ramping up capital and business alliances, M&A, and
investments in promising fields.
Our corporate venture capital fund, established in 2023 to address
women’s health issues, has steadily expanded its portfolio and now invests in eight companies. We are
also advancing our human resources strategy by nurturing individuals who embrace challenges and can
respond to environmental change and global expansion. Under Strengthen Shareholder Returns, we have
shifted from our previous stable dividend policy to a performance-linked profit-sharing method
indicating a dividend payout ratio of 30%, also setting a minimum dividend per share to ensure ongoing
consideration for dividend stability.
In FY2024, we increased the annual dividend per share by ¥15 to
¥55, and we expect to pay an annual dividend of ¥55 in FY2025 as well (interim dividend of ¥27 and
year-end dividend of ¥28).
Under Strengthen IR Activities, we continue to hold financial results briefings twice annually and have
been working to expand IR opportunities through initiatives such as one-on-one meetings with
institutional investors and information sessions for individual investors. Furthermore, we have won
increased recognition from outside the Company for our efforts to enhance the content of our integrated
report, and in FY2024 we received the Best IR Award for Encouragement by the Japan Investor Relations
Association.
The Best IR Award for Encouragement is a great honor, as it underscores widespread
recognition of our IR efforts. We have maintained return on equity (ROE), a benchmark for evaluating
corporate value, at over 8% since FY2021 and expect to achieve our target of 8% in FY2025, the final
year of Medium-Term Management Plan 2025. We will continue working to sustainably enhance ROE and
demonstrate consistent growth to the market.
To maintain ROE above the cost of shareholders’ equity,
we are working to improve our product mix by focusing on the high-margin new drug business, while also
enhancing the profitability of our core pharmaceutical business and expanding overseas operations. In
our next medium-term management plan, which is currently being formulated, we aim to further improve ROE
through the implementation of new business strategies. Through these initiatives, we seek to overcome
challenges such as rising personnel and material costs and drug price revisions, and aim to strengthen
our earnings base and achieve sustainable growth.
Although our price-to-earnings ratio (PER), which
plays an important role as a measure of corporate value alongside ROE, remains slightly below the
industry average, it has been steadily improving. Enhancing both ROE and PER will contribute to a higher
PBR. We have fostered this positive cycle through initiatives such as disclosing our policies on
management conscious of cost of capital and share price and strengthening IR activities, raising PBR
from around 0.6x in 2023 to above 1x at present. However, we recognize that surpassing 1x is only a
starting point and that further improvement is necessary.
We aim to improve PBR by enhancing our
reputation, establishing a clear growth story, strengthening communication not only with institutional
investors but also with individual investors, and deepening understanding and support for our business
activities.
In addition to enhancing profitability, optimizing the capital structure remains an
important priority. We are rigorously managing working capital and fixed assets while continuing to
reduce cross-shareholdings deemed to have limited strategic significance. These efforts to improve asset
efficiency are expected to contribute to higher ROE, which in turn should lead to improvements in PER
and PBR. As of March 31, 2025, cross-shareholdings accounted for 16.7% of consolidated net assets, down
1.7 percentage points from the previous fiscal year-end.
We will continue to monitor ROE, PER, and PBR as inter-related indicators and work to further strengthen this virtuous cycle through profit growth, improved capital efficiency, and dialogue with investors, with the goal of maximizing corporate value.
Reduction in Cross-Shareholdings
PBR (price-to-book ratio) and ROE (return on equity)
PBR has remained at around 1.0x, while ROE has consistently exceeded 8% in recent years. For the fiscal year ended March 31, 2025, PBR stood at 1.02x and ROE at 8.0%.
Approach to the Cost of Equity
Our Group is committed to managing its business with a strong awareness of the cost of capital. Based on
the view that the equity spread, calculated by subtracting the cost of equity from ROE, is generally
positively correlated with PBR, we are working not only to improve ROE but also to reduce the cost of
equity.
We recognize that there are various ways of assessing the cost of equity. In a broad sense,
however, we believe that the cost of capital borne by a company when raising capital represents the rate
of return that investors expect from investing in the company. In this context, we believe that IR
activities play an important role.
If a company takes a passive approach to IR and provides
insufficient disclosure regarding its financial position and business activities, investors may find it
difficult to adequately identify the risks and opportunities associated with the company. As a result,
investment in the company may be perceived as higher risk, leading investors to require a higher
expected rate of return.
Conversely, if a company maintains a policy of providing sufficient
disclosure and avoiding unexpected surprises for investors, investment in the company may be perceived
as lower risk. This can lower investors’ expected rate of return and, consequently, contribute to
reducing the company’s cost of equity.
Based on this approach, we will further strengthen our IR
activities, seek to reduce our effective cost of equity, and work together with our shareholders and
investors to enhance corporate value.
Continue to take initiatives to swiftly achieve a PBR of above 1x
1. Growth strategy
(Updated: June 2026)
- Implementation of growth strategy
- Optimal cash allocation
Cash Allocation ResultsPlan for FY2023–2025
Cash Allocation Plan for FY2026–2028
2. Strengthen shareholder returns
(Updated: June 2026)
- Beginning in the fiscal year ending March 2027, the Company will provide shareholder returns with a target total payout ratio of 40%, while aiming to enhance dividend levels in line with earnings growth.
- To clearly demonstrate our commitment to returning profits to shareholders, we have adopted a progressive dividend policy (excluding special dividends). Under this policy, we will, in principle, maintain or increase dividends and avoid dividend reductions, thereby ensuring stable and sustainable shareholder returns.
Trend in Dividend per Share (% indicates dividend payout ratio)
3. Strengthen IR activities
- Creation of dialogue opportunities
- Expansion of information disclosures
Dialogue with Shareholders and Investors (FY2023)
| Activities | Results (Previous FY) | Company Representatives |
|---|---|---|
| Financial Results Briefings | 2 (2) | Management |
| Broker-Sponsored Conferences and Meetings | 3 (1) | Management |
| IR Events for Individual Investors | 2 (1) | IR Department |
| IR Event for Institutional Investors (Pipeline Briefing) | 1 (1) | Management |
| Individual IR Meetings / SR Dialogue | 100 meetings 110 companies / 163 participants (cumulative) (79 meetings) |
Management / IR & SR Department |
Governance
Basic Approach
Our Company continuously pursues the highest standards of corporate governance and is committed to its ongoing enhancement based on the following fundamental principles:
- We strive to ensure that shareholders’ rights are effectively protected and that all shareholders are treated equitably.
- We work to engage appropriately with stakeholders and foster a corporate culture that respects ethical business conduct.
- We appropriately disclose the Company’s financial, managerial, and other information to ensure transparency.
- The Board of Directors establishes an environment that enables bold management decisions based on corporate strategy, while exercising highly effective oversight of directors.
- We engage in constructive dialogue with shareholders.
Non-Financial Strategies
“We aim to achieve our financial targets and contribute to the realization of the SDGs by addressing social issues through our business activities.”
- Our Purpose
Mid-Term Management Plan 2028
- Slogan
FY2028 Financial Targets
-
Net Sales
¥85.0billion -
Operating Profit Margin
10% -
ROE
10% -
Total payout ratio
40%
The Five Pillars Driving Growth
-
Domestic
PharmaceuticalStrengthening
Profitability through
Further Expansion
in Specialty Areas -
Drug Discovery
Accelerating Global Expansion
-
Global
Strengthening Business Foundations through New Plant Operations
-
Animal
HealthExpanding Business through
New Product Launches and Overseas Expansion -
Testing and
Around-the-PillExpanding the Testing Business through Trace Analysis Technologies and Broadening into Adjacent Healthcare Fields
Two Strategic Foundations
-
Financial Strategy
Advanced management with a focus on the cost of capital
-
Strengthening the Management Foundation
Strengthening the management infrastructure to execute strategies
6 Material Issues
-
1
Promotion of environmental management
-
2
Developing diverse human resources to enhance corporate value
-
3
Contributing to women's health and animal health
-
4
Stable supply of high-quality products and provision of appropriate information
-
5
Respect for human rights
-
6
Strengthening governance
Promotion of Sustainability
The ASKA Pharmaceutical Holdings Group pursues ESG management so that it can solve social issues through its business. In this, we are guided by the corporate philosophy, “Contribute toward the improvement of people’s health and progress in society through the development of innovative products.”
The Group has identified 11 material issues (most important issues). Of these, “contribution to women’s health” and “contribution to animal health” are particularly relevant material issues for the Company and are being promoted by the entire Group. We will also work to address climate change by reducing CO2 emissions through expanded use of solar power generation and the introduction of clean energy, and strengthen our human capital by developing and acquiring human resources capable of responding to new businesses and changes in the business and social environment, and by creating a working environment in which a diverse range of human resources, including women, career professionals, and seniors, can play an active role.
In April 2023, we established a new Sustainability Promotion Section in the Corporate Planning Department with the aim of further accelerating our efforts. We will continue to meet the expectations of our stakeholders by placing sustainability at the center of our management, striking a balance between maximizing the economic value of the Company and enhancing its social value.
ASKA Pharmaceutical Holdings
Senior Managing Member of the Board of Directors,
Representative Director, in charge of Sustainability
Atsushi Maruo
Basic Policy for Sustainability
The Company has established CSR guiding principles and works for the ongoing growth for the Group as a
whole and to contribute to society.
As a trusted company, we will increase profitability through
sound business practices and fulfill our social responsibilities as a good corporate citizen.
- Supplying High-Quality Pharmaceuticals
- All employees conduct business with integrity guided by our corporate philosophy.
- We provide a stable supply of high-quality pharmaceuticals with excellent efficacy and safety profiles.
- Ensuring Compliance
- We are thoroughly committed to corporate ethics and to compliance with all laws and regulations.
- We maintain fair relationships with stakeholders and conduct transactions that are fair, transparent, and based on free competition.
- Regarding the protection of personal information, we manage the information in compliance with our privacy policy.
- Respecting Human Rights
- We respect the human rights of all people affected by our business practices.
- We respect the diversity of our employees and strive to foster a safe and comfortable corporate culture.
- Contributing to Communities and Society
- As a good corporate citizen, we communicate with the local community and broader society while striving to contribute to the world.
- Preserving the Environment
- We participate in the realization of a sustainable society through environmental preservation and by practicing environmental management.
Materiality Map
Mapping of Material Issues
The Group aims to become a total healthcare company with a strong foundation as a specialty pharma
company. To contribute to solving social issues and building a sustainable society, we identified 17
materialities unique to our Company at the launch of the ESG Committee in 2021 (reorganized to 11 in
October 2023, and further reorganized to 6 in April 2025).
In particular, “Contribution to Women’s
Health and Animal Health” is considered a materiality where our strengths can be maximized. Based on the
Medium-Term Management Plan, the Group works on these materialities as a priority, contributing to the
realization of a sustainable society and aiming to enhance corporate value from a medium- to long-term
perspective through sustainable growth and the creation of social value.
KPIs and SDGs for Material Issues
Materiality items that are particularly significant to the Group are highlighted in red. Quantitative targets are highlighted in blue.
| ESG | Materiality | KPI | SDGs |
|---|---|---|---|
| E | Promotion of Environmental Management |
* This materiality will, for the time being, apply only to domestic business activities. |
|
| S | Development of Diverse Human Resources for Enhancing Corporate Value |
|
|
| Contributing to Women’s Health and Animal Health |
|
|
|
| Stable Supply of High-Quality Products and Proper Information Provision |
|
|
|
| Respect for Human Rights |
|
|
|
| G | Strengthening Governance |
|
|
Major Material Issue Initiatives Achievements
This section introduces the results of our efforts for material issue KPIs that are of particular
interest to our stakeholders.
Our ESG Committee will oversee material issue initiatives and drive
improvements.
| E: Promotion of Environmental Management *Limited to domestic business activities | |
|---|---|
| Corresponding SDGs |
|
| KPI | FY2025 First Half Progress |
|---|---|
| CO2 Emissions Reduction: Companywide target – 60% reduction vs FY2013 (by
FY2035) Target at domestic production site (Iwaki Factory): 60% reduction vs FY2013 (by FY2030) |
|
| Reduction of Total Waste and Maintenance/Improvement of Recycling Rate of 90% or
Higher: Waste plastic recycling rate of 65% or higher (by FY2030) |
|
| Environmentally Conscious Business Operations |
|
| Reduction of Environmentally Harmful Substances (Reduction of Nitrogen Load through Promotion of Low-Protein Feed) |
|
| Promotion of Biodiversity |
|
| Thorough Supply Chain Management and Preferential Procurement of Environmentally Friendly Products |
|
| S: Development of Diverse Talent to Enhance Corporate Value | |
|---|---|
| Corresponding SDGs |
|
| KPI | Progress Report (First Half of FY2025) |
|---|---|
| Promoting Autonomous Learning (20 hours per employee per year) |
|
| Promoting Diverse Work Styles: Remote Work, Location-Specific Roles, Shortened Working Hours / Target Work Engagement Ratio: 40% or higher |
|
| Promoting Women’s Empowerment (FY2029 Targets): Ratio of Female Managers: 20% / Ratio of Female Manager Candidates: 30% |
|
| Initiatives for Work–Life Balance (Diversity): Work Support Incentive / Average Paternity Leave of 30 Days or More |
|
| Annual Paid Leave Utilization Rate: 80% or Higher (Company-Wide Average) |
|
| Maintaining an Effective ICT Environment to Facilitate Flexible Work and Enhance Productivity |
|
| Developing Digital Transformation (DX) Talent to Improve Operational Efficiency, Organizational Productivity, and Work–Life Balance |
|
| S: Contributing to Women’s Health and Animal Health | |
|---|---|
| Relevant SDGs |
|
| KPI | Progress Report for the First Half of FY2025 |
|---|---|
| Contribution to Healthcare through Disease Awareness and Dissemination of Accurate Knowledge in Specialty Areas (Obstetrics & Gynecology, Thyroid Disorders) |
|
| Initiatives for Providing Information on Sex Education and Reproductive Health from Adolescence through Childrearing |
|
| Promotion of Animal Welfare |
|
| Development and Provision of Products Contributing to the Health of Companion and Livestock Animals |
|
| Promotion of Academic Activities Related to Veterinary Medicines and Associated Diseases (Especially Reproductive and Endocrine Disorders) |
|
| Promotion of In-house Research Themes and Strengthening of Alliance Activities |
|